23andMe Holding Co. (OQ:ME)

Business Focus: Medical & Diagnostic Laboratories

Oct 11, 2024 08:15 am ET
23andMe Announces 1-for-20 Reverse Stock Split
23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company’s Class A and Class B common stock will become effective as of 12:01 a.m. EST on October 16, 2024 (the “Effective...
Oct 08, 2024 07:00 am ET
23andMe Announces Mathew Knowles as New Brand Ambassador
23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today announced an ongoing collaboration with Mathew Knowles, father of Beyoncé and Solange Knowles, well-known entrepreneur, global leader in sales and...
Oct 01, 2024 06:52 am ET
ME INVESTOR NOTICE: Current 23andMe Holding Co. Shareholders are Notified to Contact BFA Law about Investigation into the Board of Directors (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 29, 2024 06:40 am ET
ME INVESTOR UPDATE: Shareholders of 23andMe Holding Co. are Alerted of Pending Investigation into the Company; Contact BFA Law if You Own Substantial Shares (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 27, 2024 06:16 am ET
ME INVESTIGATION NOTICE: The Investigation into 23andMe Holding Co. is Ongoing – Contact BFA Law if You are a Current Shareholder (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 25, 2024 07:30 am ET
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today released a new report on the genetics of emotional eating for 23andMe+ Premium members, informing them if they are at a higher likelihood of frequent...
Sep 25, 2024 07:11 am ET
ME SHAREHOLDER UPDATE: 23andMe Holding Co. is Under Investigation for Breaches of Fiduciary Duties; Current Shareholders are Urged to Contact BFA Law (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 24, 2024 09:30 am ET
Barrack, Rodos & Bacine Is Investigating 23andMe Holding Co.
The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ: ME) regarding the mass resignation of all of the independent members of the board of directors following the presentation of an offer by the CEO and co-founder,...
Sep 23, 2024 11:45 am ET
Barrack, Rodos & Bacine Is Investigating 23andMe Holding Co.
The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ: ME) regarding the mass resignation of all of the independent members of the board of directors following the presentation of an offer by the CEO and co-founder,...
Sep 23, 2024 06:18 am ET
ME INVESTIGATION NOTICE: 23andMe Holding Co.’s Board of Directors is Being Investigated; Current Shareholders are Urged to Contact BFA Law (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 21, 2024 07:13 am ET
ME INVESTOR UPDATE: 23andMe Shareholders are Notified to Contact BFA Law about Ongoing Investigation into the Company for Breaches of Fiduciary Duties (Nasdaq:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 19, 2024 11:25 am ET
Wolf Popper LLP is Investigating Whether the Offer to Acquire 23andMe Holding Co. By Its Controlling Shareholder Is Fair to the Minority Shareholders
Wolf Popper LLP is investigating claims on behalf of investors in 23andMe Holding Co. (NASDAQ: ME) concerning the offer to acquire 23andMe by its controlling shareholder, Anne Wojcicki, who is 23andMe’s co-founder and CEO. Under the terms of the...
Sep 19, 2024 07:07 am ET
ME STOCK ALERT: 23andMe Holding Co. Shareholders are Notified that an Investigation has been Initiated Against the Company’s Board of Directors and are Urged to Contact BFA Law (NASDAQ:ME)
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their...
Sep 17, 2024 04:26 pm ET
Independent Directors of 23andMe Resign from Board
The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in which the independent directors...
Sep 15, 2024 03:00 am ET
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from its Phase 1/2a clinical trial covering two new patient cohorts from...
Sep 15, 2024 03:00 am ET
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced nonclinical data supporting the anti-tumor activity of its first-in-class 23ME-01473 (’1473) antibody targeting the NKG2D ligand ULBP6...
Sep 12, 2024 04:05 pm ET
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at National Human Genome Research Institute, part of the National Institutes of Health (NIH), and Johns...
Sep 03, 2024 07:30 am ET
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that it will display three poster presentations on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an...
Aug 28, 2024 07:30 am ET
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing...
Aug 15, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 14, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 13, 2024 01:00 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 12, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Aug 09, 2024 12:15 pm ET
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 08, 2024 04:05 pm ET
23andMe Reports First Quarter Fiscal 2025 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter of fiscal year 2025 (FY25), which ended June 30, 2024. Key Results and Recent Developments Reported...
Aug 08, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 07, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 06, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / August 6, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 05, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Aug 02, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Aug 02, 2024 08:00 am ET
23andMe Special Committee responds to CEO’s take-private proposal
The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the...
Aug 01, 2024 08:00 am ET
23andMe Announces CEO’s Take-Private Proposal
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has received a preliminary non-binding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of...
Jul 25, 2024 04:45 pm ET
23andMe to Report Q1 FY2025 Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Jul 25, 2024 07:30 am ET
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lung Cancer...
Jul 19, 2024 11:50 am ET
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the potential take-private transaction of 23andMe Holding Co. (NasdaqCM: ME) (the “Company”).
Jun 28, 2024 07:00 am ET
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s...
Jun 14, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Jun 06, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Jun 05, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Jun 05, 2024 07:00 am ET
23andMe Launches New Genetic Report on Bipolar Disorder
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher...
Jun 04, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Jun 04, 2024 07:00 am ET
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration...
Jun 03, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Jun 03, 2024 08:00 am ET
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024...
May 31, 2024 12:15 pm ET
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
May 30, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 29, 2024 12:15 pm ET
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 29, 2024 08:00 am ET
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, with support from The Michael J. Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new...
May 28, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / May 28, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 23, 2024 04:05 pm ET
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent...
May 23, 2024 12:30 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / May 23, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 22, 2024 01:00 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 20, 2024 12:30 pm ET
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 20, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 17, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / May 17, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 16, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
May 16, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 14, 2024 12:15 pm ET
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 14, 2024 07:00 am ET
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil)...
May 10, 2024 12:15 pm ET
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 09, 2024 04:50 pm ET
23andMe to Report Q4 and Full Year FY2024 Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
May 09, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
May 08, 2024 12:30 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 07, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
May 06, 2024 12:15 pm ET
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Apr 24, 2024 04:05 pm ET
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024...
Apr 18, 2024 08:00 am ET
23andMe announces CEO’s intention to pursue a potential take-private
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal...
Apr 05, 2024 04:05 pm ET
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23ME-01473 targeting ULBP6, and 23ME-00610 targeting CD200R1, at the American Association...
Mar 20, 2024 07:30 am ET
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors. The target for the...
Mar 19, 2024 08:00 am ET
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individuals, from...
Mar 06, 2024 07:30 am ET
23andMe Launches New Genetic Reports on Common Forms of Cancer
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as...
Mar 05, 2024 04:30 pm ET
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral presentation and two poster presentations on two of the Company’s immuno-oncology programs that will be presented at the...
Feb 27, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 26, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 26, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 22, 2024 12:10 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 22, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 21, 2024 12:15 pm ET
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 20, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 16, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 15, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 14, 2024 12:15 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 13, 2024 12:15 pm ET
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / February 13, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 12, 2024 12:10 pm ET
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
The hackers specifically targeted the personal genetic information of Jewish and Chinese customers and compiled that data - including genetic heritage, names, and addresses - into lists that were then sold on the dark web, but 23andMe concealed both those revelations when it announced the extent of the breach in December 2023.
Feb 09, 2024 12:15 pm ET
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / February 9, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Feb 07, 2024 04:01 pm ET
23andMe Reports Third Quarter Fiscal 2024 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7...
Jan 31, 2024 07:30 am ET
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application for 23ME-01473 (‘1473), a natural killer...
Jan 30, 2024 10:12 pm ET
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program. Seat16 allows anyone to...
Jan 24, 2024 04:05 pm ET
23andMe to Report FY2024 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Dec 19, 2023 08:00 am ET
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the further expansion of the ongoing 23ME-00610 Phase 1/2a study to include an additional 30 patients with advanced neuroendocrine and...
Dec 05, 2023 09:00 am ET
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (NASDAQ: ME) Data Breach
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- 23andMe, a popular personal genomics and DNA analysis company run by 23andMe Holding Co. ("23 and Me") (NASDAQ: ME), recently suffered a massive data leak. The attack targeted the personal information of 23andMe users -more than 4 million people- compromising individual's personal information such as full name, birth year, email address, and sex, along with information on genetic ancestry, potential relatives, and geolocation. 
Nov 13, 2023 04:30 pm ET
PRIVACY ALERT: Genetic Testing Company 23andMe Faces Class Action Investigation for Cyberattack Potentially Impacting Five Million Customers
23andMe Customers Are Urged to Contact Schubert Jonckheer & Kolbe LLP to Discuss Their Legal Rights
Nov 08, 2023 04:05 pm ET
23andMe Reports Second Quarter Fiscal 2024 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023. Recent Highlights Consumer...
Nov 07, 2023 08:00 am ET
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing,...
Nov 06, 2023 08:00 am ET
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced data from its ongoing first-in-human Phase 1/2a clinical trial evaluating the safety and efficacy of 23ME-00610, an investigational...
Oct 31, 2023 08:00 am ET
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data,...
Oct 30, 2023 08:00 am ET
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which extends their collaboration and enables GSK to conduct drug target discovery and other research using the 23andMe...
Oct 25, 2023 04:05 pm ET
23andMe to Report FY2024 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Sep 27, 2023 04:05 pm ET
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of...
Sep 14, 2023 07:00 am ET
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, and the non-profit Sickle Cell 101, have joined forces to expand awareness of people’s sickle cell carrier status. The collaboration will include...
Aug 31, 2023 05:28 pm ET
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected...
Aug 08, 2023 04:05 pm ET
23andMe Reports FY2024 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with...
Jul 31, 2023 08:30 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating 23andMe Holding Co. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, July 31, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of 23andMe Holding Co. (NASDAQ: ME).
Jul 25, 2023 04:05 pm ET
23andMe to Report FY2024 First Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Jul 20, 2023 09:23 am ET
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person's likelihood of...
Jun 21, 2023 07:00 am ET
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ subscription service on the genetics of panic attacks, or episodes of intense anxiety with...
May 25, 2023 04:05 pm ET
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4)...
May 16, 2023 07:00 am ET
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
23andMe Holding Co. (Nasdaq: ME) (23andMe) today announced that a new survey, which found that primary care physicians are more and more comfortable discussing genetic testing with their patients than they were two years ago, and that more than...
May 11, 2023 04:05 pm ET
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on...
May 09, 2023 07:00 am ET
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune disease that can in some severe cases lead to permanent tissue damage, and may affect the...
May 08, 2023 07:00 am ET
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its...
Apr 14, 2023 04:05 pm ET
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced results from the Phase 1 portion of its Phase 1/2a study evaluating 23ME-00610, an investigational antibody targeting CD200R1....
Apr 11, 2023 07:00 am ET
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
Today, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, Morehouse School of Medicine (MSM), and the Sickle Cell Foundation of Georgia (SCFG) announced the launch of a Sickle Cell Carrier Status...
Mar 29, 2023 07:01 am ET
23andMe Publishes Inaugural Environmental, Social and Governance Report
ESG report outlines strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations
Mar 24, 2023 07:00 am ET
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to increase...
Mar 14, 2023 04:30 pm ET
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting...
Mar 09, 2023 09:00 am ET
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
A large percentage of people and doctors in the US say that using genetic testing could make healthcare more personalized and effective, according to new surveys by 23andMe. The data comes from two national surveys on attitudes from both primary...
Feb 28, 2023 07:00 am ET
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the human genome, dosed the first patient in the Phase 2a portion of its Phase...
Feb 22, 2023 04:05 pm ET
23andMe to Present at Upcoming Investor Conferences
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in...
Feb 08, 2023 04:05 pm ET
23andMe Reports FY2023 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3)...
Jan 26, 2023 04:05 pm ET
23andMe to Report FY2023 Third Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Dec 01, 2022 12:00 pm ET
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported survey results on how US adults are feeling...
Nov 14, 2022 08:00 am ET
23ANDME (ME) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating 23andMe For Potential Securities Violations and Breaches of Fiduciary Duty
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against 23andMe Holding Co. (“23andMe” or the...
Nov 07, 2022 04:01 pm ET
23andMe Reports FY2023 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the second quarter...
Nov 07, 2022 08:00 am ET
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, is presenting a trials-in-progress poster detailing tumor...
Oct 27, 2022 06:45 am ET
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported that the U.S. Food and Drug Administration...
Oct 24, 2022 04:05 pm ET
23andMe to Report FY2023 Second Quarter Financial Results
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the...
Oct 12, 2022 04:10 pm ET
23andMe to Present at Upcoming Investor Conferences
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be participating in...
Oct 05, 2022 08:21 am ET
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present a trials-in-progress...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.